Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...

Genentech is letting go of 118 employees in San Francisco. The news comes about two months after the biotech ended a ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...

Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...

Aldeyra has since resubmitted its application, buffing it up with a “single clinical trial that achieved the primary endpoint ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in ...

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...